… to reduce the IgM-AMA but not IgG-AMA levels in peripheral blood mononuclear cells from
Japanese PBC patients after bacterial CpG … in liver cirrhosis caused by autoimmune liver …

… Currently, ursodeoxycholic acid (UDCA) is the treatment of choice for this disease. … M (IgM),
the elevation of NK and NKT cells, as well as noticeable hyperresponsiveness to CpG …

… The treatment of PBC is ursodeoxycholic acid (UDCA), which halts the progression of the …
suggest that CpG-B [170] may be a potential endogenous trigger of B cells to produce IgM and …

… features such as immune system CpG oligodeoxynucleotide … with PBC severity and
ursodeoxycholic acid (UDCA) treatment … B cells may also induce IgM production by these B cells …

… IgM level and treatment response to ursodeoxycholic acid (UDCA) in patients with primary
biliary cholangitis … the clinical data of 637 PBC patients who were diagnosed and treated with …

… licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-… on the CPG panel,
and patient representatives were invited … IgM, which may be driven by epigenetic changes [45]. …

… Although ursodeoxycholic acid (UDCA) and obeticholic acid (… benefit patients with PBC; it
could normalize the IgM levels … involving the nucleotide cytosine in CpG sites, which typically …

… Ursodeoxycholic acid (UDCA) is the first line therapy (13–15 … However, although partial and
variable methylation on CpG … was also associated with increased serum IgM levels. Later on, …

… controls after an exposure to CpG, which is a … to ursodeoxycholic acid (UDCA) (54). After
the treatment, serum levels of total IgG, IgM, and IgA as well as those of AMA-IgA and AMA-IgM …

… of treatment remains the bile acid ursodeoxycholic acid (UDCA). … greater amounts of IgM
after stimulation with CpG‐B [18]. … -B after rituximab treatment resulted in significantly lower IgM …